Get the Stockscreener App
47.63
1.04%
-0.50
After Hours:
47.63
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Capstone Investment Advisors LLC Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Vestal Point Capital LP Sells 1,050,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Suvretta Capital Management LLC Sells 910,112 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Alkeon Capital Management LLC - MarketBeat
Acuta Capital Partners LLC Purchases New Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx to Participate in Investor Conferences in December - GlobeNewswire
Ultragenyx to Present at Three Major Healthcare Investor Conferences in December | RARE Stock News - StockTitan
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail
CDKL5 Deficiency Disorder Market Revenue to Expand - openPR
Algert Global LLC Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Massachusetts Financial Services Co. MA Purchases 172,126 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Swiss National Bank Grows Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Boosted by Natixis Advisors LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Sells 87,626 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Top 10 startups in Rare Diseases in Bay Area, United States in Nov, 2024 - Tracxn
B. Metzler seel. Sohn & Co. Holding AG Takes $1.32 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Hypophosphatasia Market 2034: Epidemiology Review, Pipeline - openPR
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $40.23 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Principal Financial Group Inc. Acquires 76,150 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Grants 20,820 RSUs to New Officers in Four-Year Vesting Plan | RARE Stock News - StockTitan
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $86.69 Consensus PT from Analysts - MarketBeat
State of New Jersey Common Pension Fund D Has $1.93 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Osteogenesis Imperfecta Treatment Market 2024-2031: Global - openPR
How To Trade (RARE) - Stock Traders Daily
RTW INVESTMENTS, LP Adjusts Stake in Ultragenyx Pharmaceutical I - GuruFocus.com
Ultragenyx Pharmaceutical's SWOT analysis: pipeline progress boosts rare disease stock - Investing.com
Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy - MSN
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
Ultragenyx: Ready For More Growth After Q3 Earnings Beat (NASDAQ:RARE) - Seeking Alpha
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Research Analysts Offer Predictions for RARE FY2024 Earnings - MarketBeat
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates - MSN
Ultragenyx posts data for Angelman syndrome therapy (RARE:NASDAQ) - Seeking Alpha
Ultragenyx Presents Positive Update on GTX-102 Angelman - GlobeNewswire
Ultragenyx's Angelman Treatment Shows 80% Patient Improvement in Phase 1/2 Trial | RARE Stock News - StockTitan
What is Wedbush's Estimate for RARE FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Negative Outlook of RARE FY2024 Earnings - MarketBeat
What is HC Wainwright's Estimate for RARE FY2024 Earnings? - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Estimate for RARE Q1 Earnings? - MarketBeat
Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - MarketBeat
Ultragenyx Pharma stock target raised, retains buy on strong revenue growth - Investing.com India
HC Wainwright Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00 - MarketBeat
Ultragenyx Pharma stock target raised, retains buy on strong revenue growth By Investing.com - Investing.com South Africa
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts - Benzinga
International Assets Investment Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx: Excellent Company, Lackluster Stock (NASDAQ:RARE) - Seeking Alpha
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... - Yahoo Finance
Ultragenyx Reports Strong Q3 Growth and Milestones - TipRanks
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024 - Marketscreener.com
Ultragenyx Pharmaceutical reports an over 40% increase in Q3 revenue - North Bay Business Journal
Ultragenyx Pharmaceutical Q3 2024 Earnings Preview - MSN
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings: Revenue S - GuruFocus.com
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):